<DOC>
	<DOCNO>NCT00130143</DOCNO>
	<brief_summary>Dry mouth occurs often patient receive radiation treatment . Amifostine drug approve reduce short long-term occurrence dry mouth patient receive radiation treatment head neck cancer . Some study show Amifostine reduces side effect radiation treatment lung cancer . The use Amifostine still investigate lung malignancy . Amifostine find protectant radiation side effect normal tissue bone marrow , skin , oral mucosal , esophagus , kidney testis . Patients receive radiation treatment lung cancer may experience side effect involve esophagus . It hop patient benefit protection esophagus avoid delay radiation treatment due side effect radiation .</brief_summary>
	<brief_title>Toxicities Associated With Subcutaneous Administration Ethyol ( Amifostine ) Prevention Radiation-Induced Toxicities</brief_title>
	<detailed_description>The protective capacity thio-containing compound normal tissue damage radiation recognize 40 years.. Although intravenous administration approve standard route , practical advantage increase interest subcutaneous administration Ethyol , present multiple advantage use radioprotection . Based data present , well personal experience physicians/centers subcutaneous administration amifostine , researcher propose open-label study evaluate rate severity toxicity associate route administration . Toxicities assess include nausea/vomiting , hypotension , skin/fever reaction .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Patient eligible receive subcutaneous amifostine site â€™ current practice guideline radioprotection . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Age &gt; 18 Patient receive radiation therapy combine modality therapy treat malignancy . No evidence distant metastatic disease . Granulocyte count ( segs &amp; band ) &gt; 2000/mm3 platelet count &gt; 100,000/mm3 Serum creatinine &lt; 2.0mg/dL Total bilirubin &lt; 2.0mg % , SGOT &lt; time upper limit normal . Patients may enter investigational therapeutic trial . Patients guardian must inform understand investigational nature study give write informed consent prior study procedure . Life expectancy &lt; 6 month Patients receive chemotherapy treat malignancy . Patients treat investigational drug &lt; 4 week prior study entry . General medical psychological condition would permit patient complete study sign inform consent . Pregnancy ; Women childbearing potential use effective ( ) method birth control throughout participation study . Patients currently receive receive amifostine radioprotection within prior 6 month exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
</DOC>